Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alterity Therapeutics Limited - American Depositary Shares (NQ:ATHE)

4.250 +0.060 (+1.43%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,350
Open 4.220
Bid (Size) 4.160 (5)
Ask (Size) 4.280 (1)
Prev. Close 4.190
Today's Range 4.090 - 4.270
52wk Range 1.001 - 7.000
Shares Outstanding 2,084,016,678
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire

Performance

YTD
+13.9%
+13.9%
1 Month
-16.2%
-16.2%
3 Month
+9.8%
+9.8%
6 Month
+46.6%
+46.6%
1 Year
+193.1%
+193.1%

More News

Read More
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Present at the Biotech Showcase
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Prominently Featured at the International MSA Congress
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Raises A$40.0 million in Placement
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Wondering what's happening in today's after-hours session?
Via Chartmill

Frequently Asked Questions

Is Alterity Therapeutics Limited - American Depositary Shares publicly traded?
Yes, Alterity Therapeutics Limited - American Depositary Shares is publicly traded.
What exchange does Alterity Therapeutics Limited - American Depositary Shares trade on?
Alterity Therapeutics Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alterity Therapeutics Limited - American Depositary Shares?
The ticker symbol for Alterity Therapeutics Limited - American Depositary Shares is ATHE on the Nasdaq Stock Market
What is the current price of Alterity Therapeutics Limited - American Depositary Shares?
The current price of Alterity Therapeutics Limited - American Depositary Shares is 4.250
When was Alterity Therapeutics Limited - American Depositary Shares last traded?
The last trade of Alterity Therapeutics Limited - American Depositary Shares was at 10/03/25 03:59 PM ET
What is the market capitalization of Alterity Therapeutics Limited - American Depositary Shares?
The market capitalization of Alterity Therapeutics Limited - American Depositary Shares is 8.86B
How many shares of Alterity Therapeutics Limited - American Depositary Shares are outstanding?
Alterity Therapeutics Limited - American Depositary Shares has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.